Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alta Partners

This article was originally published in Start Up

Executive Summary

Alta Partners, a spin out of the former Burr Egan & Deleage venture capital firm, has a contrarian view of health-care in this age of Internet enthusiasm. It continues to invest about half of its funds in health care on the assumption that investment preferences are cyclical and health care will see a rebound within 3-5 years. Guy Nohra, a partner at Alta, bases this prediction in the unprecedented discoveries going on in the human genome, as well as the increase in NIH funding for R&D. Alta has made a number of investments since incorporating three years ago, including the high-profile deCode Genetics Inc., which did a major deal with Roche. Other investments are Radiant Medical Inc., BioInterventional, Aclara Biosciences Inc., and Ilex.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC090003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel